988 Results

People

  1. Lesokhin
    Lesokhin
  2. Landgren
    Landgren
  3. Hassoun
    Hassoun
  4. Mailankody
    Mailankody
  5. Landau
    Landau
  6. Giralt
    Giralt
  7. Korde
    Korde
  8. Hultcrantz
    Hultcrantz
  9. Chung
    Chung
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)
  7. Sloan Kettering Institute Postdocs (292)
  8. Bone Marrow Transplant (289)
  9. Epidemiology and Biostatistics (209)
  10. Biostatistics Service (175)
  1. "Myeloma"
Formats
  1. Meeting Abstract (543)
  2. Journal Article (358)
  3. Review (36)
  4. Research Letter (19)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)

More Groups

People
  1. Alexander Lesokhin (363)
  2. Carl Landgren (336)
  3. Hani Hassoun (329)
  4. Sham Mailankody (282)
  5. Malin Hultcrantz (260)
  6. Heather Landau (239)

More People

Years
  1. 2025 (13)
  2. 2024 (69)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (303)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (22)

More Publications

Publishers
  1. American Society of Hematology (324)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (83)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (988)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial
    Meeting Abstract

    Richardson, P. G.; Jacobus, S. J.; Weller, E.; Hassoun, H.; Lonial, S.; Raje, N. S.; Medvedova, E.; McCarthy, P. L.; Libby, E. N.; Voorhees, P. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma (RRMM): DREAMM-14
    Meeting Abstract

    Salwender, H.; Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R.; Byrne, J.; Eliason, L.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma: The author's reply
    Correspondence

    Mailankody, S.; Brentjens, R. J.; Smith, E. L.
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Clinical trial participation among older adult Medicare fee-for-service beneficiaries with cancer
    Journal Article

    Green, A. K.; Tabatabai, S. M.; Aghajanian, C.; Landgren, O.; Riely, G. J.; Sabbatini, P.; Bach, P. B.; Begg, C. B.; Lipitz-Snyderman, A.; Mailankody, S.
    JAMA Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI
    Meeting Abstract

    Usmani, S. Z.; Martin, T. G.; Berdeja, J. G.; Jakubowiak, A. J.; Agha, M. E.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A. M.; Munshi, N. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Patel, K.; Sano, D.; Maris, M.; Lesokhin, A. M.; Von Keudell, G.; Doucette, K.; Ramchandren, R.; Pavlov, D.; Uger, R. A.; Molloy, N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma
    Meeting Abstract

    Patel, K.; Orlowski, R. Z.; Doucette, K.; Maris, M.; Pianko, M. J.; Ramchandren, R.; Stevens, D. A.; Vesole, D. H.; Uger, R. A.; Scheuber, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM)
    Meeting Abstract

    Lesokhin, A. M.; Arnulf, B.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Tomasson, M. H.; Rodríguez-Otero, P.; Quach, H.; Raje, N. S.; Iida, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm
    Meeting Abstract

    Kumar, S.; Bianchi, G.; Biran, N.; Hultcrantz, M.; Richter, J. R.; Vij, R.; Ye, J. C.; Zonder, J. A.; DiLello, L.; Yesil, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save